These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6388985)

  • 1. Dysfibrinogenemia. A current perspective.
    Galanakis DK
    Clin Lab Med; 1984 Jun; 4(2):395-418. PubMed ID: 6388985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal binding of calcium to five fibrinogen variants with mutations in the carboxy terminal part of the gamma-chain.
    Furlan M; Stucki B; Steinmann C; Jungo M; Lämmle B
    Thromb Haemost; 1996 Sep; 76(3):377-83. PubMed ID: 8883274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen anomalies and disease. A clinical update.
    Galanakis DK
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1171-87. PubMed ID: 1400080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation.
    Rodeghiero F; Castaman GC; Dal Belin Peruffo A; Dini E; Galletti A; Barone E; Gastaldi G
    Thromb Haemost; 1987 Jun; 57(3):252-8. PubMed ID: 2958952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital dysfibrinogenemia.
    Rupp C; Beck EA
    Curr Probl Clin Biochem; 1984; 14():65-130. PubMed ID: 6150812
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
    Robert-Ebadi H; Le Querrec A; de Moerloose P; Gandon-Laloum S; Borel Derlon A; Neerman-Arbez M
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):697-9. PubMed ID: 18832913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I).
    de Bosch NB; Mosesson MW; Ruiz-Sáez A; Echenagucia M; Rodriguez-Lemoin A
    Thromb Haemost; 2002 Aug; 88(2):253-8. PubMed ID: 12195697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new type of Ser substitution for gamma Arg-275 in fibrinogen Kamogawa I characterized by impaired fibrin assembly.
    Mimuro J; Kawata Y; Niwa K; Muramatsu S; Madoiwa S; Takano H; Sugo T; Sakata Y; Sugimoto T; Nose K; Matsuda M
    Thromb Haemost; 1999 Jun; 81(6):940-4. PubMed ID: 10404772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
    Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
    Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Congenital dysfibrinogenemias. A review.
    Rocha E; Páramo JA; Aranda A; Cuesta B; Fernández J
    Ric Clin Lab; 1985; 15(3):205-29. PubMed ID: 3909359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
    Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
    Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assembly and structure of the fibrin clot.
    Mosesson MW
    Nouv Rev Fr Hematol (1978); 1992; 34(1):11-6. PubMed ID: 1523091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paris I dysfibrinogenemia: a point mutation in intron 8 results in insertion of a 15 amino acid sequence in the fibrinogen gamma-chain.
    Rosenberg JB; Newman PJ; Mosesson MW; Guillin MC; Amrani DL
    Thromb Haemost; 1993 Mar; 69(3):217-20. PubMed ID: 8470043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly.
    Mosesson MW
    Blood Coagul Fibrinolysis; 1997 Jul; 8(5):257-67. PubMed ID: 9282789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen and dysfibrinogenemia.
    Morse EE
    Ann Clin Lab Sci; 1980; 10(4):351-5. PubMed ID: 7447388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of coagulation screening test results in two cases having dysfibrinogen].
    Terasawa F; Sasaki Y; Ishikawa S; Nakagoshi R; Furihata K; Katsuyama T; Okumura N
    Rinsho Byori; 1996 Aug; 44(8):791-6. PubMed ID: 8816067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
    Terasawa F; Kani S; Hongo M; Okumura N
    Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization.
    Lu PD; Galanakis DK; Ghebrehiwet B; Peerschke EI
    Clin Immunol; 1999 Mar; 90(3):360-7. PubMed ID: 10075865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.